<DOC>
	<DOCNO>NCT00509067</DOCNO>
	<brief_summary>This study evaluate effectiveness galantamine CDP-choline improving symptom associate schizophrenia .</brief_summary>
	<brief_title>Use Galantamine CDP-choline ( Citicoline ) Treat Adults With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia life-long brain disorder affect approximately 1 percent Americans year . Schizophrenia extremely disable , cause people hear voice , experience paranoia hallucination , believe others control thought , even fail maintain job care . Current medication help relieve negative symptom , . Many people schizophrenia still suffer low energy level , inability concentrate , memory loss . Galantamine medication use improve memory energy level people Alzheimer 's disease , CDP-choline nutritional supplement . The purpose study evaluate effectiveness add galantamine CDP-choline stable anti-psychotic medication regimen risperidone way improve symptom adult schizophrenia . Participants double-blind study attend initial screen undergo physical exam , electrocardiogram , blood urine collection . Participants randomly assign receive galantamine CDP-choline placebo treatment 16 week . Participants assign treatment group take 500 mg CDP-choline daily first 3 day , 1,000 mg daily next 4 day , 2,000 mg daily follow 15 week . Participants assign treatment group also take 8 mg galantamine daily first week , 16 mg daily next week , 24 mg daily follow 14 week . Participants assign control group take two type placebo pill every day 16 week . All participant continue take regular regimen risperidone , olanzapine , quetiapine , ziprasidone , and/or aripiprazole throughout trial addition assign treatment . Staff member meet participant first week study every 4 week afterward study completion . During meeting , participant identify side effect , report nicotine intake , breathe machine measure amount nicotine body , complete write computerized task concentration memory . Each meeting may last 3 hour . On last week study , blood urine sample collect electrocardiogram administer . Results study used evaluate whether CDP-choline galantamine improve schizophrenia symptom . CDP-choline match placebo purchase LifeLink Corporation . Galantamine match placebo prepare donated Ortho McNeil Janssen Scientific Affairs LLC .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>Meets DSMIV criterion schizophrenia schizoaffective disorder Eligible care within Veterans Affairs Medical system Taking risperidone , olanzapine , quetiapine , ziprasidone , and/or aripiprazole ( oral injection ) Significant liver , kidney , lung , endocrine , active peptic ulcer , cardiovascular disease Seizure disorder and/or head injury Substance use abuse within 3 month study entry Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Acetylcholine</keyword>
	<keyword>Nicotinic Receptors</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Galantamine</keyword>
	<keyword>negative symptom</keyword>
</DOC>